Ariad Pharmaceuticals Inc

Type: Company
Name: Ariad Pharmaceuticals Inc
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power

PHOENIX, Oct. 20, 2014 /PRNewswire/ -- Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Halliburton (NYSE:HAL), Ariad Pharmaceuticals (NASDAQ:ARIA), KeyCorp ... [Published Nation's Restaurant News - 18 hours ago]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

ARIAD PHARMACEUTICALS : and Bellicum Announce Revised License Agreement for 's Cell-Signaling Technology

By a News Reporter-Staff News Editor at Pharma Business Week -- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Bellicum Pharmaceuticals, Inc. announced a restructuring of their license agreement for ARIAD's cell-signaling technology. ARIAD will receive ... [Published 4 Traders - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

16.9% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)

SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 16.90% as of today's recent price of $5. ... [Published Individual.com - Oct 15 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 2 reports

Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics

/PRNewswire/ --Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. ( NASDAQ: ARIA ), Novavax Inc. ( NASDAQ: NVAX ), Galena Biopharma Inc. ( NASDAQ: GALE ), Geron Corporation ( NASDAQ: GERN ), and Celldex Therapeutics ... [Published U-T San Diego - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

ARIAD's Iclusig Gains Positive Recommendation from PRAC

Sometimes, drugs marketed by pharma/biotech companies are required to be assessed by regulatory agencies to determine the risks associated with the use of the drug. In the EU, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee ... [Published Zacks.com - Oct 14 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 2 reports

ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens. Following the announcement, at…Click to Continue » ... [Published Fort Mills Times - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Ariad Pharmaceuticals Makes a Move: Up 3.8%

One of today's stocks on the move is Ariad Pharmaceuticals (NASDAQ:ARIA), up 3.8% to $5.21. The Dow is up 0.6% to 16,426 and the S&P is currently up 0.9% to 1,892. ... [Published Individual.com - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

ARIAD and Bellicum restructure license agreement for cell-signaling technology

ARIAD Pharmaceuticals, Inc., an oncology company, and Bellicum Pharmaceuticals, Inc., a developer of cell therapies to treat cancers, have announced restructuring of their license agreement for ARIAD's cell-signaling technology. ARIAD will receive $50 ... [Published Individual.com - Oct 14 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 12 reports

PRAC Decision On Leukemia Drug Good News For Ariad Pharmaceuticals, Inc., Says Analyst

October 10, 2014By Riley McDermid , BioSpace.com Breaking News Sr. EditorNews that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended the use ofAriad Pharmaceuticals, Inc. ( ARIA )' leukemia drug ... [Published BioSpace - Oct 10 2014]
First reported Oct 06 2014 - Updated Oct 07 2014 - 10 reports

ARIAD and Bellicum announce revised license agreement for ARIAD’s cell-signaling technology

ARIAD Pharmaceuticals, and Bellicum Pharmaceuticals, announced a restructuring of their license agreement for ARIAD’s cell-signaling technology. ... [Published PBR - News - Oct 07 2014]
First reported Oct 02 2014 - Updated Oct 03 2014 - 8 reports

Ariad's Lung Cancer Drug Receives FDA Breakthrough Therapy Designation

Ariad Pharmaceuticals, Inc. announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive ... [Published Drug Discovery and Development - Oct 02 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 6 reports

UPDATE 2-Ariad Pharma's lung cancer drug gets breakthrough therapy status

(Adds further comments from company)Oct 2 (Reuters) - Ariad Pharmaceuticals Inc saidits experimental lung cancer drug was granted "breakthroughtherapy" status by the U.S. Food and Drug Administration and itexpected to file for marketing approval in early ... [Published Reuters - Oct 02 2014]

Quotes

"The amended agreement with Bellicum allows ARIAD to realize substantial non-dilutive funding from our legacy program based on small-molecule regulation of cell signaling, while maintaining our strategic focus on bringing breakthrough medicines to cancer patients in need" said Harvey J Berger , M D , chairman and chief executive officer of ARIAD
Geron Corp. "s stock finished Tuesday's session 1.08% higher at $1.87 . A total of 1.66 million shares were traded, which was below its three months average volume of 2.25 million shares. The stock moved between $1.80 and 1.95 during the session. Geron Corp." s shares have declined 3.61% in the previous three trading sessions and 23.98% in the last one month. Additionally, the stock has lost 58...
"We are very pleased that the FDA has granted Breakthrough Therapy designation to AP26113," stated Harvey J Berger, M D , chairman and CEO of ARIAD. "We are encouraged by the clinical data on AP26113 that were presented recently at the European Cancer Congress, particularly in patients whose tumor had spread to the brain. We are focused on accelerating patient enrollment in the ongoing ALTA trial and on planning a front-line trial of AP26113 in treatment-naive patients."
...You don't find one answer. You have to have different answers for different people," he said. "Not every cancer is the same. Even with one person, you have to adapt the medicine as the cancer adapts."

More Content

All (184) | News (141) | Reports (0) | Blogs (35) | Audio/Video (0) | Fact Sheets (1) | Press Releases (7)
sort by: Date | Relevance
Biggest Movers in Healthcare Stocks Now – NPSP ... [Published InvestorPlace.com - 13 hours ago]
Insider Trading Research for Halliburton, Ariad... [Published Nation's Restaurant News - 18 hours ago]
Insider Trading Research for Halliburton, Ariad... [Published Financial Services - 18 hours ago]
Cowen: Best Buys, Favorable Biotech Outlook Remain [Published BioSpace - Oct 17 2014]
ARIAD PHARMACEUTICALS : and Bellicum Announce R... [Published 4 Traders - Oct 16 2014]
Hottest Healthcare Stocks Now – ARIA CLVS HZNP ... [Published InvestorPlace.com - Oct 15 2014]
16.9% Return Seen to Date on SmarTrend Ariad Ph... [Published Individual.com - Oct 15 2014]
Biotech Equities Technical Analysis - ARIAD Pha... [Published U-T San Diego - Oct 15 2014]
Biotech Equities Technical Analysis - ARIAD Pha... [Published PR Newswire: Health - Oct 15 2014]
ARIAD to Webcast Conference Call on Third Quart... [Published Fort Mills Times - Oct 15 2014]
ARIAD to Webcast Conference Call on Third Quart... [Published Business Wire Health News - Oct 15 2014]
ARIAD's Iclusig Gains Positive Recommendation f... [Published Zacks.com - Oct 14 2014]
Ariad Pharmaceuticals Makes a Move: Up 3.8% [Published Individual.com - Oct 14 2014]
ARIAD and Bellicum restructure license agreemen... [Published Individual.com - Oct 14 2014]
Amgen's Blinatumomab Gets Priority Review in th... [Published Zacks.com - Oct 13 2014]
Highlights from EMA Pharmacovigilance October m... [Published Pharma Letter - Oct 12 2014]
PRAC Decision On Leukemia Drug Good News For Ar... [Published BioSpace - Oct 10 2014]
Ariad’s Harvey Berger says he’s ‘absolutely’ se... [Published Boston Business Journal - Oct 10 2014]
No Change to Approved Indication for Ariad's Ic... [Published PharmTech.com - Oct 10 2014]
Ariad Pharmaceuticals, Inc. Announces Recommend... [Published BioSpace - Oct 10 2014]
EMA's PRAC backs Iclusig [Published Seeking Alpha - Oct 10 2014]
EMA committee backs Ariad's Iclusig, but calls ... [Published FirstWord Pharma - Oct 10 2014]
EU agency backs continued use of Ariad leukemia... [Published DailyMe.Com - Oct 10 2014]
ARIAD Announces Recommendation For Iclusig By T... [Published Atlanta Journal And Constitution - Oct 10 2014]
ARIAD Pharma: PRAC Recommends No Change To Appr... [Published RTTNews.com - Oct 10 2014]
ARIAD Announces Recommendation For Iclusig By T... [Published Benzinga.com - Oct 10 2014]
EU agency backs continued use of Ariad leukaemi... [Published Yahoo! Finance - Oct 10 2014]
ARIAD Announces Recommendation for Iclusig by t... [Published Business Wire - Oct 10 2014]
ARIAD Announces Recommendation for Iclusig by t... [Published Business Wire Health News - Oct 10 2014]
Ariad’s Lung Cancer Drug Gets FDA Breakthrough ... [Published Bioresearch Online - Oct 08 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biotech Equities Technical Analysis - ARIAD Pha... [Published PR Newswire: Health - Oct 15 2014]
LONDON, October 15, 2014 /PRNewswire/ --Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation (NASDAQ: GERN), and ...
ARIAD to Webcast Conference Call on Third Quart... [Published Business Wire Health News - Oct 15 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens. Following the announcement, at 8:30 a.m. ...
ARIAD Announces Recommendation for Iclusig by t... [Published Business Wire Health News - Oct 10 2014]
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig® ...
ARIAD and Bellicum announce revised license agr... [Published PBR - News - Oct 07 2014]
ARIAD Pharmaceuticals, and Bellicum Pharmaceuticals, announced a restructuring of their license agreement for ARIAD’s cell-signaling technology. ...
Wayfair shares surge [Published FOX Business - Video - Oct 06 2014]
FBN’s Lauren Simonetti on Wayfair’s market performance, Westport Innovations’ 2014 revenue forecast and Ariad Pharmaceuticals’ experimental lung cancer drug. ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
Insider Trading Research for Halliburton, Ariad... [Published Financial Services - 18 hours ago]
Technical Data on Biotech Stocks - ARIAD Pharma... [Published Financial Services - Sep 04 2014]
The Zacks Analyst Blog Highlights: AbbVie, Shir... [Published Financial Services - Aug 01 2014]
Biotech Stocks Technical Data -- MannKind, ARIA... [Published Financial Services - Aug 01 2014]
Clinical Studies, Trials Results, Appointments,... [Published Financial Services - Jun 27 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.